1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment

MLA

Filippo Alongi, et al. “1.5 T MR-Guided and Daily Adapted SBRT for Prostate Cancer: Feasibility, Preliminary Clinical Tolerability, Quality of Life and Patient-Reported Outcomes during Treatment.” Radiation Oncology, vol. 15, no. 1, Mar. 2020, pp. 1–9. EBSCOhost, https://doi.org/10.1186/s13014-020-01510-w.

APA

Filippo Alongi, Michele Rigo, Vanessa Figlia, Francesco Cuccia, Niccolò Giaj-Levra, Luca Nicosia, Francesco Ricchetti, Gianluisa Sicignano, Antonio De Simone, Stefania Naccarato, Ruggero Ruggieri, & Rosario Mazzola. (2020). 1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment. Radiation Oncology, 15(1), 1–9. https://doi.org/10.1186/s13014-020-01510-w

Chicago

Filippo Alongi, Michele Rigo, Vanessa Figlia, Francesco Cuccia, Niccolò Giaj-Levra, Luca Nicosia, Francesco Ricchetti, et al. 2020. “1.5 T MR-Guided and Daily Adapted SBRT for Prostate Cancer: Feasibility, Preliminary Clinical Tolerability, Quality of Life and Patient-Reported Outcomes during Treatment.” Radiation Oncology 15 (1): 1–9. doi:10.1186/s13014-020-01510-w.